ClinicalTrials.gg

Cerebral Hemorrhage clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 458 studies for Cerebral Hemorrhage across more than 10 countries. 173 are recruiting or about to start. 280 of them are mainly about Cerebral Hemorrhage (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
160
Recruiting
114
Status unknown
69
Not yet recruiting
55
Terminated
28
Active, not recruiting
20

Phase

Phase 2
79
Phase 3
42
Phase 1
31
Phase 4
16
Early Phase 1
3

Where

China
123
United States
109
Germany
29
Canada
26
France
24
United Kingdom
24

Who develops what

Add Cerebral Hemorrhage to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 29 Dec 2026 est.N-Acetylcysteinamide · Arctic Therapeutics · Phase 2 named, not the main aimNCT07716865 Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) — primary endpoint: Incidence of Treatment-Emergent Adverse Events · 15 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cerebral Hemorrhage studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Factor Xa inhibitors 3 open · NSAIDs 3 open · Thrombolytics 2 open · Statins 2 open · Antifibrinolytics 1 open

Coming up

48studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 114 Cerebral Hemorrhage studies recruiting now, 60 (53%) set no upper age limit and 9 (8%) stop at 75 or younger. 3 (3%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (5%) take healthy volunteers.

Recruiting studies that take each age, of 114
AgeWomenMen
102 (2%)2 (2%)
18103 (90%)103 (90%)
30109 (96%)109 (96%)
40110 (96%)110 (96%)
50112 (98%)112 (98%)
65114 (100%)114 (100%)
75105 (92%)105 (92%)
8574 (65%)74 (65%)

Across all 458 studies, recruiting or not: 8% stop at 75 or younger and 4% at 65; 7% take children; <1% are for women only and 0% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cerebral Hemorrhage studies take

Of 24 phase 2 interventional studies under Cerebral Hemorrhage, half reached primary completion within 38 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 238 mo28–62 · 24 studies——
Interventional, no phase38 mo19–72 · 85 studies—38 mo19–75 · 77 studies
Observational62 mo27–179 · 89 studies—62 mo30–179 · 87 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 458. Browse all 458 → or search them.